BRAF and neoplasm: For patients who do not carry the BRAF mutation or who have relapsed after TT, other therapeutic strategies exist consisting in the administration of immune checkpoint blockade (ICB) agents such as anti-PD-1, anti-PDL1, and anti-CTLA4 antibodies aimed at reactivating immune responses against tumor cells [25, 26].